FOSUN HEALTH Logo

IgA Nephropathy Treatment

catalogue

IgA Nephropathy Treatment

IgA Nephropathy Treatment

Treatment for IgA nephropathy runs in a strict order, and the order matters more than any individual drug. Supportive care — blood pressure, proteinuria, salt, cardiovascular risk — is the foundation for everyone, and it is where most of the lifetime benefit comes from. Immune-directed therapy comes afterwards, only for people still at high risk, and only with the infection risk honestly weighed. This page walks that order, then covers the aggressive presentations, the integrated pathway, and what the long term involves.

Supportive care: the foundation that applies to everyone

Every person with this disease is treated with supportive care, whatever their biopsy shows and whether or not they ever receive anything else. The reason is mechanical: pressure inside the filtering unit drives protein through an inflamed filter, and sustained high pressure is what turns inflammation into permanent scarring. Lowering that pressure slows the disease regardless of what started it.

Component What it does What it asks of the patient
Blood pressure control, with an ACE inhibitor or angiotensin receptor blocker Lowers pressure inside the filtering unit rather than only in the arm, which reduces protein leak and slows scarring Taken daily and long-term; potassium and creatinine checked after starting and after any dose change
An SGLT2 inhibitor where proteinuria persists Reduces protein leak and protects filtration through a mechanism independent of blood pressure and of blood sugar A daily tablet, with an expected small initial dip in filtration that is not a reason to stop; hydration and genital hygiene matter
Sodium restriction Makes both of the above work better, and lowers blood pressure and swelling on its own The hardest component in practice: mostly a matter of what is cooked with, and of processed food
Cardiovascular risk management Statin, smoking cessation, weight and activity — because cardiovascular disease is the commonest competing risk in this population Reviewed at the same appointments rather than referred elsewhere and forgotten
Avoiding what stresses the kidney Non-steroidal anti-inflammatory drugs, dehydration during illness, and unnecessary contrast exposure A short list that has to be remembered at the moment of a headache or a fever, which is when it is forgotten
Vaccination and infection planning Reduces the infections that provoke episodes, and matters more if immune therapy is later used Influenza, pneumococcal and others as advised, kept up to date rather than arranged at the point of need

In practice: blood pressure is generally aimed below a systolic of 120 mmHg where tolerated, and proteinuria pushed as low as it can go, with a level under 0.5 g a day commonly used as the aim. Neither is reached in a single visit — optimising supportive care takes three to six months, and that period is the treatment rather than a delay before it.

It is also worth saying what supportive care prevents. People with this disease are more likely to die of cardiovascular disease than to reach kidney failure, and the same measures that protect the kidney protect the heart. That is why this section is the longest on the page and why the prevention page is written for patients rather than only for clinicians.

Immunosuppression: for whom, and at what cost

Immune-directed therapy is the part of this disease that patients ask about first and that guidelines place last. It is not the main treatment; it is an addition for the minority in whom the risk of progression remains high after supportive care has been maximised, and its cost is infection.

Option Where it fits What has to be weighed
A time-limited course of corticosteroid Proteinuria that remains substantial after supportive care has been optimised, with filtration still reasonably preserved Serious infection has been seen with full-dose regimens in this disease. Generally avoided when filtration is already severely reduced, in people with diabetes, and where infection risk is high; where used, prophylaxis against opportunistic infection is part of the plan
Mycophenolate mofetil Used in some centres and some populations, including in China, particularly where steroid exposure needs to be limited Evidence outside those populations has been less supportive, and it is not a standard first choice everywhere. It is also teratogenic, which shapes its use in younger patients
Cyclophosphamide with steroid The rapidly progressive crescentic form, where function is being lost over weeks rather than years A genuine emergency measure with real toxicity; used because the alternative is losing the kidney, not because it is mild
Azathioprine or other steroid-sparing agents Maintenance after an induction course, or where repeated steroid courses would otherwise be needed Monitoring of blood counts and liver function; the benefit is in reducing steroid exposure rather than in treating the disease directly
Tonsillectomy Practised widely in Japan, often combined with steroid pulses The evidence base is not conclusive and it is not standard practice elsewhere. It is a reasonable question to ask, and it is not a substitute for supportive care
Fish oil and other supplements Once widely recommended; no longer routinely advised Not harmful at ordinary doses, but it should not displace treatments with evidence behind them, and it should be declared — some supplements affect the kidney or interact with prescribed medicines

The discipline that matters is the order. A patient started on immune therapy before blood pressure is controlled, salt is reduced and an SGLT2 inhibitor has been given its three months is being given the risk without the benefit, because a large part of what looks like treatment failure at that point is unoptimised supportive care. Establishing that the foundation is genuinely in place is the single most useful thing a second opinion can do, and it is the first thing our assessment checks.

Treatments developed specifically for this disease

Until recently there was no medicine licensed for IgA nephropathy itself — everything used was borrowed from other kidney diseases. That has changed, and it is the reason a patient diagnosed today faces a different conversation from one diagnosed ten years ago.

Targeted-release budesonide is the clearest example of the new logic. The abnormal IgA1 is produced by immune tissue in the lining of the small intestine, so this is a steroid formulated to be released there — acting on the source while largely sparing the rest of the body. It is given as a time-limited daily course, and it is approved in the United States for adults with this disease who are at risk of progression. Because it is a steroid, it is not risk-free, and it is prescribed with the same caution about infection and about glucose and bone effects.

Sparsentan blocks two pathways at once — the angiotensin receptor and the endothelin receptor — and is approved in the United States under an accelerated pathway on the basis of proteinuria reduction. It sits alongside, not instead of, an ACE inhibitor or angiotensin receptor blocker in the way it is used, and it requires monitoring of liver function, blood pressure, potassium and fluid status.

Two framing points keep this section honest. Availability and licensing differ between countries, so a medicine approved in one place may be accessible in another only through a specific route, and a patient should ask what is actually available where they will be treated. And none of these replace the foundation underneath them: they are added to optimised supportive care, and a patient who stops the blood pressure medicine because a new drug has been started has undone most of the benefit.

The aggressive presentations that need a different response

A small group presents differently: filtration falls over weeks rather than years, the urine shows heavy protein and many casts, and the biopsy shows crescents in a large proportion of the filtering units. This is rapidly progressive glomerulonephritis, managed as an emergency.

What distinguishes it is the tempo. A creatinine that doubles in six weeks, or proteinuria at nephrotic levels appearing together with a fall in filtration, is not the ordinary course of this disease and should not be observed for another three months. It needs a biopsy read urgently, with the crescent score reported rather than filed.

The treatment is correspondingly more aggressive: high-dose steroid with cyclophosphamide in the crescentic form, and plasma exchange where the picture overlaps with an antibody-mediated disease or where crescentic disease progresses despite immunosuppression. Our nephrology service provides double plasma exchange and hybrid blood purification, alongside peritoneal dialysis catheter placement and vascular access establishment and maintenance, in the same unit that runs the outpatient and inpatient kidney service.

What should also be said is what this presentation is not. It is uncommon, and most people reading this page will never experience it. Its purpose here is to define the threshold at which waiting is no longer the right move, and to make clear that where function is being lost quickly, the response has to happen in a unit that can biopsy, read, immunosuppress and purify in the same admission.

The integrated Chinese and Western medicine pathway

Many patients arriving at our service ask specifically about Chinese medicine, and the honest answer is that it is available, that it is delivered alongside conventional nephrology rather than instead of it, and that the numbers that decide whether treatment is working do not change.

The traditional Chinese medicine department runs a dedicated kidney disease clinic. Patients who want a combined approach are managed across both services: blood pressure, proteinuria and filtration handled with the medicines and targets described above, and an individualised Chinese medicine regimen prescribed alongside, with the two clinicians aware of what the other has prescribed.

What this is not, and what we say to every patient who asks, is a substitute. A herbal regimen does not bring blood pressure to target on its own and does not replace an ACE inhibitor or an SGLT2 inhibitor. Two questions decide whether a combined pathway is reasonable: is the prescription visible to the nephrologist, and are protein and filtration still being measured at the same intervals?

There is one specific benefit worth noting, because it is about the shape of care rather than about any remedy: a clinic structured around a single condition, with shorter intervals and a clinician who reviews the same numbers repeatedly, is a setting in which supportive care actually gets optimised. That is the part of the pathway that changes outcomes.

Living with the disease over decades

A diagnosis made at thirty is a diagnosis that has to fit around a working life, and the practical management of it is mostly unremarkable once the pattern is established. What follows are the things that come up most often.

Question What we advise
How often should tests be repeated? Set by the risk rather than by the calendar: protein and filtration every few months while the trajectory is being established, and less often once it is stable. The biopsy score and the filtration trend decide the interval, not how the patient feels
Can I exercise and work normally? Yes. Ordinary exercise is encouraged. What is asked is hydration during prolonged exertion, and avoiding the non-steroidal anti-inflammatory drugs that people reach for afterwards
What about infections? Treat them promptly and mention the diagnosis when a medicine is prescribed, because the anti-inflammatories and some antibiotics need adjusting. Vaccinations are kept up to date, and more so if immune therapy is ever used
Can I take anti-inflammatory painkillers? Occasional use is a conversation rather than a prohibition, but regular use in this disease is a real problem. Paracetamol is the ordinary alternative, and the reason should be explained rather than simply forbidden
What about pregnancy? Plan it with the nephrology team. The risk is set largely by blood pressure, proteinuria and filtration at the time of conception, and several of the medicines used in this disease are changed before conception rather than during pregnancy
Should my family be tested? Familial clustering exists but this is not a simple inherited disease, so routine screening of relatives is not standard. A first-degree relative with persistent unexplained haematuria is worth a urine test and a mention
What should I keep? A record of your own numbers — protein, creatinine, blood pressure, with dates. A trend reconstructed from memory is not reliable, and a trend written down is the most useful thing you can bring to any appointment, including a remote one

That last point is why the practical questions page begins with records rather than with travel: the patient who owns their own numbers can get a considered opinion from their own country before deciding whether to come at all.

Frequently Asked Questions

Why is blood pressure treatment called the main treatment?

Because it changes the outcome more than the immune-directed medicines do, for more people. Pressure inside the filtering unit is what drives protein through an inflamed filter, and sustained high pressure converts inflammation into scarring. An ACE inhibitor or angiotensin receptor blocker lowers that internal pressure directly, which is why they are preferred over other agents here. Add sodium restriction and an SGLT2 inhibitor where protein persists, and most of the lifetime benefit has been delivered before immune therapy is discussed.

If steroids reduce inflammation, why not take them?

Because the benefit appears only in people at high risk, and the harm is concentrated where the benefit is least. Trials in this disease have shown serious infection with full-dose regimens. A time-limited course may be considered when proteinuria stays high after supportive care is optimised, and is generally avoided when filtration is already severely reduced, in diabetes, or where infection risk is high.

Are there treatments designed specifically for this disease now?

There are, and this is the biggest change in the field in a decade. Targeted-release budesonide is a steroid formulated to be released where the abnormal IgA1 is produced, acting on the source while largely sparing the rest of the body. Sparsentan blocks two pathways at once and is approved under an accelerated pathway on the basis of proteinuria reduction. Availability differs between countries, and neither replaces the supportive care underneath them.

What happens if the disease reaches kidney failure?

It is planned for rather than reacted to, and the planning starts years earlier. The options are haemodialysis, peritoneal dialysis and transplantation, and each needs preparation: a fistula formed and given weeks to mature, a catheter placed and a training period, or a transplant workup with a possible living donor. IgA nephropathy can recur in a transplanted kidney, so follow-up continues, but transplantation here has good outcomes and is the preferred destination.

Patient Stories

Stories from our iga nephropathy programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

Check whether the foundation is in place before anything else

Send your protein and creatinine measurements with dates, your blood pressure readings, your current medicines including anything bought over the counter, and any biopsy report you hold. Our team will return a written opinion on whether supportive care has been optimised, whether immune therapy is genuinely indicated in your case, and which treatments are actually available here — before any travel is arranged.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*